BUSAN, South Korea, May 23, 2013 /PRNewswire/ -- Pusan National University Yangsan Hospital, in collaboration with SillaJen, Inc., a private biotherapeutics and contract research company focused on research and development of targeted biological products for cancer, announced today a publication reporting the induction of functional anti-cancer antibodies in patients treated with the oncolytic and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.).
This research was published in the May 15th, 2013 issue of the journal Science Translational Medicine. The co-senior and co-corresponding authors were Dr. Tae-Ho Hwang (Director of the Pusan National University Yangsan Hospital Clinical Research Center; SillaJen Chief Scientific Officer) and Dr. David Kirn (Jennerex founder and Advisor to SillaJen). The authors reported data from patients treated with JX-594 on Phase 1 and 2 clinical trials, as well as from rabbit tumor model studies. The authors demonstrated functional anti-cancer immunity induction, specifically including antibody-mediated complement-dependent cytotoxicity (CDC) in patients' serum targeting cancer cells. Phase 1 data showed a correlation between patients' survival duration and a measure of CDC intensity. No autoimmune toxicities were reported in treated patients, including long-term survivors.
"This research was led by the laboratory group at SillaJen and Pusan National University, working closely with scientists at Jennerex. These findings, published in the premier research journal Science Translational Medicine, represent a landmark for the field of oncolytic immunotherapies for cancer," said Dr. Tae-Ho Hwang . "We were able to demonstrate for the first time that functional immune responses were induced against cancer cells following JX-594 treatment. T
|SOURCE Pusan National University|
Copyright©2012 PR Newswire.
All rights reserved